Vol 7 No 1 (2025)

• Patent Analysis of Osimertinib in China

  Wei-Xing Chen

  Abstract: Osimertinib is a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI), used in the treatment of non-small cell lung cancer (NSCLC) patients harboring the EGFR T790M mutation. This paper conducts a comprehensive analysis of invention patents related to osimertinib in China. It includes statistics and evaluations on applicant rankings, applicant countries, application-publication trends, technical distribution, and authorization rates. Furthermore, a focused analysis is carried out on AstraZeneca’s key patent portfolio in China. This study aims to provide insight into the technological development trends, hotspots, and focal points in this feld, ofering valuable reference for pharmaceutical enterprises engaging in related R&D.

  PDF

• Research Progress on the Current Status and Risk Factors of Postoperative Delirium in Elderly Patients Undergoing Urological Surgery

  Yi-Chun Zheng, Liang-Hao Lin

  With the rapid acceleration of population aging in China, the number of elderly patients undergoing urological surgery has increased year by year, accompanied by a rising incidence of postoperative delirium (POD). This article provides a comprehensive review of the current status, clinical characteristics, and associated risk factors of postoperative delirium in elderly urological patients. Patient-related factors such as advanced age, multiple comorbidities, cognitive impairment, and malnutrition significantly increase the risk of POD. In addition, perioperative factors—including inappropriate preoperative medication use, the extent of surgical trauma, choice of anesthesia, and inadequate postoperative pain management—also play critical roles. A thorough understanding of these risk factors is beneficial for clinicians to develop targeted preventive strategies and to improve postoperative recovery outcomes in elderly patients.

  PDF